 |
 |
Phoenix Pharmaceuticals, Inc 
|
 |
萨路森-阿尔法免疫试剂盒和抗体
一个新的心血管多肽
Salusin -alpha (Human) and Salusin (50-mer) (Human) RIA Kits
| Salusin beta is a surrogate ligand of the
mas-like G protein-coupled receptor MrgA1 |
| |
| Wang Za, Takahashi Tb, Saito Yc, Nagasaki Hd,
Ly NKa, Nothacker HPa, Reinscheid RKa, Yang Je, Chang JKe, Shichiri
Mf, Civelli Oa. |
a: Department of Pharmacology, University
of California, Irvine, CA 92697, USA. |
| b: Suntory Insitute for Bioorganic Research,
Wakayamadai, Shimamotocho, Mishimagun, Oskaka, 618-8503,
Japan |
| c: Department of Pharmacology, Saitama Medical
School, Morohongo, Saitama, 350-0495, Japan |
| d: Nagoya University, School of Medicine,
Clinical Research Bldg., Nagoya City, Aichi, 466-8550,
Japan |
| e: Phoenix Pharmaceuticals, Inc., Blemont,
CA 94002, USA |
| f: Tokyo Medical and Dental Univeristy Medical
Hospital, Yushima, Bunkyo-ku, Tokyo, 113-8519 |
| |
The mas-like G protein-coupled receptors
form a subfamily of G protein-coupled receptors that
includes variable member numbers across different species
and that have been shown to bind a wide variety of ligands
from peptides to amino acid derivatives. While screening
a library of peptides against different orphan G protein-coupled
receptors, we found that human salusin beta activates
the mouse mas-like G protein-coupled receptor, mMrgA1
with an EC(50) of about 300 nM. Salusin beta is a bioactive
peptide recently discovered through bioinformatics analysis
which stimulates arginine-vasopressin release from rat
pituitary and causes rapid and profound hypotension and
bradycardia. However, when we further analyzed the generality
of the mMrgA1 activation, we found that human salusin
beta does not activate corresponding human mas-like G
protein-coupled receptors. Our results show that human
salusin beta is a surrogate ligand of the mouse MrgA1
and raises a cautionary flag for experiments that analyze
the pharmacological profiles of mas-like G protein-coupled
receptors from different species. |
| Eur
J Pharmacol. 2006 Jun 13;539(3):145-50.
Epub 2006 Apr 5. |
萨路森-阿尔法免疫试剂盒 Salusin-alpha (Human) RIA Kit , EDTA plasma extraction required |
|
|
Salusin (50-mer) (Human) RIA Kit |
|
|
|
|
| |
| EC50 values for agonist compounds at mMrgA1 |
| Peptide |
EC50 (nM) +- S.E.M. |
Catalog No. |
| Salusin-a (Human) |
NR* |
010-67 |
| Salusin-b (Human) |
295.8 +- 4.0 |
010-68 |
| Salusin (50-mer) (Human) |
116.8 +- 2.9 |
010-73 |
| Salusin (40-mer) (Human) |
87.9 +- 5.1 |
010-74 |
| BAM-22 |
>1000** |
024-07 |
| Cortistatin-14 (rat) |
>1000** |
060-04 |
| FMRF amide |
>1000** |
047-29 |
|
*NR: no response at 1 mM;
** >1000: has response at 1 mM but not saturated at 10
mM, thus EC50 cannot be determined.
Wang Z.W. et al. European Journal of Pharmacology 539
(2006), 145-150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PB-EK-010-67A |
Salusin-alpha
(Human) EIA Kit (不需样本提取） |
灵敏度: 40~60 pg/ml; 标准品范围:
40 ~ 25000 pg/ml, 样本体积:50ul
; 血清或血浆 |
| PB-EK-010-67B |
Salusin-alpha
(Rat) EIA Kit (不需样本提取） |
灵敏度: 40~60 pg/ml; 标准品范围:
40 ~ 25000 pg/ml, 样本体积:50ul ; 血清或血浆 |
| PB-EK-010-67C |
Salusin-alpha
(Human) EIA Kit |
灵敏度: 40~60 pg/ml; 标准品范围:
40 ~ 25000 pg/ml, 样本体积:50ul ; 血清或血浆 |
| PB-RK-010-67A500 |
Salusin-alpha
(人) RIA Kit (不需样本提取） |
灵敏度: 40 pg/ml; 标准品范围:
5 ~ 640 pg/ml, 样本体积:100ul ; 血清或血浆 |
| PB-RK-010-67A |
Salusin-alpha
(人) RIA Kit (不需样本提取） |
灵敏度: 40 pg/ml; 标准品范围:
5 ~ 640 pg/ml, 样本体积:100ul ; 血清或血浆 |
| PB-RK-010-67B |
Salusin-alpha
(大鼠) RIA Kit (不需样本提取） |
灵敏度: 40 pg/ml; 标准品范围:
5 ~ 640 pg/ml, 样本体积:100ul ; 血清或血浆 |
| PB-RK-010-67B500 |
Salusin-alpha
(大鼠) RIA Kit |
灵敏度: 40 pg/ml; 标准品范围:
5 ~ 640 pg/ml, 样本体积:100ul ; 血清或血浆 |
| PB-RK-010-67C |
Salusin-alpha
(大鼠) RIA Kit |
灵敏度: 40 pg/ml; 标准品范围:
5 ~ 640 pg/ml, 样本体积:100ul ; 血清或血浆 |
|
| |
| Salusins: newly identified bioactive peptides
with hemodynamic and mitogenic activities |
The discovery of endogenous bioactive peptides
has typically required a lengthy identification process. Computer-assisted
analysis of cDNA and genomic DNA sequence information can markedly
shorten the process. A bioinformatic analysis of full-length,
enriched human cDNA libraries searching for previously unidentified
bioactive peptides resulted in the identification and characterization
of two related peptides of 28 and 20 amino acids, which we designated
salusin-alpha and salusin-beta. Salusins are translated from an
alternatively spliced mRNA of TOR2A, a gene encoding a protein
of the torsion dystonia family. Intravenous administration of
salusin-alpha or salusin-beta to rats causes rapid, profound hypotension
and bradycardia. Salusins increase intracellular Ca(2+), upregulate
a variety of genes and induce cell mitogenesis. Salusin-beta stimulates
the release of arginine-vasopressin from rat pituitary. Expression
of TOR2A mRNA and its splicing into preprosalusin are ubiquitous,
and immunoreactive salusin-alpha and salusin-beta are detected
in many human tissues, plasma and urine, suggesting that salusins
are endocrine and/or paracrine factors.
|
| Shichiri M, et al. Nat Med.
2003 Sep;9(9):1166-72. Epub 2003 Aug 10. |
| 
|
|
Schematic representation of TOR2A, preprosalusin mRNA,
and the preprosalusin, prosalusin, salusin- (29Gly),
salusin-
and salusin-
proteins.
(a) Human TOR2A comprises five exons (open boxes)
and four introns (bold lines). (b) Predicted TOR2A
and preprosalusin mRNAs. Salusin polypeptides are encoded in exons
3 and 5 of TOR2A. Arrows with solid bars indicate primers
used for conventional RT-PCR. Arrows with dotted bars indicate
the positions of primers, and two small boxes denote hybridization
probes, both used for LightCycler hybridization probe format for
quantification of TOR2A (HYB-1) and preprosalusin (HYB-2).
(c) Predicted amino acid sequence of preprosalusin. An
arrowhead shows the signal-sequence cleavage site. Horizontal
bars indicate salusin polypeptides.
|
| 
|
|
Mitogenic activity of salusins.
(a) Changes in rat VSMC [Ca2+]i following
salusins, endothelin-1 and unrelated peptide (control) treatment.
Representative tracings are shown. (b) Dose-response series
of the effect of salusin-
on [Ca2+]i in rat fibroblasts. Nicardipine
and EGTA attenuate the response. Responses to endothelin-1 and
the unrelated peptide (control) are shown for comparison. (c)
Salusin-
induces proliferation of quiescent VSMCs and fibroblasts. Data
represent mean
s.e.m. of quadruplicate assays relative to control cells 72 h
after treatment. (d) Time course (left) and dose-dependent
effect (right; 2 h after treatment) of Myc induction by
salusin-
and salusin-
in quiescent VSMCs. (e) Induction of Fos by salusin-
and salusin-
in quiescent VSMCs.
|
| 
|
| (a?b>d) Anesthetized
rats for each group received the indicated doses of salusin-
(a,b) and salusin-
(c,d). Data represent the mean
s.e.m. of quadruplicate measurements relative to baseline levels. |
|
| AVP release from perifused rat
pituitaries as a function of salusin-
concentration.
Black bars indicate the time during which the indicated concentration
of salusin-
or KCl was perifused. The perifusion study was replicated four
times. |
| |
 |
|
 |
| |
| Catalog Number |
Product Name |
Quantity |
|
人民币加税 |
| RK-010-67 |
Salusin-alpha (Human) RIA Kit (extraction required) |
125 Tubes |
|
5750 |
| RK-010-73 |
Salusin (50-mer) (Human) RIA Kit (extraction required) |
125 Tubes |
|
5750 |
| H-010-70 |
Salusin-alpha (Human) Antibody |
100 ul |
|
4500 |
| 010-68 |
Salusin-beta
(Human) |
100
µg |
|
1200 |
| G-010-68A |
Salusin-beta
(Human) Antibody, Purified IgG for IHC & WB |
100
µg |
|
2000 |
| G-010-68B |
Salusin-beta
(Human) Antibody, Purified IgG for IHC & WB |
200
µg |
|
3600 |
| B-G-010-68 |
Salusin-beta
(Human) Antibody, Purified IgG, Biotin labeled |
100
µl |
|
4000 |
| H-010-68A |
Salusin-beta
(Human) Antiserum for IHC & WB |
50
µl |
|
2000 |
| H-010-68B |
Salusin-beta
(Human) Antiserum for IHC & WB |
100
µl |
|
3600 |
| H-010-67 |
Salusin-alpha
(Human) Antiserum |
50
µl |
|
2960 |
| 010-73 |
Salusin (50-mer)
(Human) |
100
µg |
|
2100 |
| T-010-73 |
Salusin (50-mer)
(Human), 125 Idoine labeled |
10 uCi |
|
5950 |
| H-010-73 |
Salusin
(50-mer) (Human) Antiserum for Immunohistochemistry
& western blot |
100
ul |
|
4500 |
| G-010-73 |
Salusin
(50-mer) (Human), Purified IgG |
200
µg |
|
4500 |
| FG-G-010-73-A |
Salusin
(50-mer) (Human), Purified IgG FAM labeled |
100
µl |
|
4950 |
| FG-G-010-73-A |
Salusin
(50-mer) (Human), Purified IgG FITC labeled |
100
µl |
|
4950 |
| B-G-010-73 |
Salusin
(50-mer) (Human), Purified IgG Biotin labeled |
100
µl |
|
4950 |
| FC3-G-010-73 |
Salusin
(50-mer) (Human), Purified IgG Cy3 labeled |
100
µl |
|
5950 |
| FC5-G-010-73 |
Salusin
(50-mer) (Human), Purified IgG Cy5 labeled |
100
µl |
|
5950 |
| 010-74 |
Salusin (40-mer)
(Human) |
100
µg |
|
2000 |
| T-010-74 |
Salusin
(40-mer) (Human), 125 Idoine labeled |
10 uCi |
|
5950 |
|
010-70 |
Salusin-alpha
-Cys0 (Human) |
100
µg |
|
|
010-69 |
Salusin-alpha
-Gly29 (Human) |
100
µg |
|
|
010-67 |
Salusin-alpha
(Human) |
100
µg |
|
|
B-010-67 |
Salusin-alpha
(Human), Biotin Labeled |
20
µg |
|
|
FC3-010-67 |
Salusin-alpha
(Human), Cy3 Labeled |
1 nmol |
|
|
FG-010-67 |
Salusin-alpha
(Human), FAM Labeled |
1 nmol |
|
|
FR-010-67 |
Salusin-alpha
(Human), Rhodamine Labeled |
1 nmol |
|
|
010-72 |
Salusin-alpha
-Tyr0 (Human) |
100
µg |
|
|
T-010-72 |
Salusin-alpha
-Tyr0 -(Human), Iodine 125 Labeled Tracer |
10
µCi |
|
|
010-71 |
Salusin-beta
-Cys0 (Human) |
100
µg |
|
|
H-010-68 |
Salusin-beta
(Human) Antiserum for IHC & WB |
100
µl |
|
|
B-010-68 |
Salusin-beta
(Human), Biotin Labeled |
20
µg |
|
|
FC3-010-68 |
Salusin-beta
(Human), Cy3 Labeled |
1 nmol |
|
|
FG-010-68 |
Salusin-beta
(Human), FAM Labeled |
1 nmol |
|
|
T-010-68 |
Salusin-beta
(Human), Iodine 125 Labeled Tracer |
10
µCi |
|
|
FR-010-68 |
Salusin-beta
(Human), Rhodamine Labeled |
1 nmol |
|
| |
|
Keywords: cardiovascular peptide, cardiovascular,
salusin, Salusin, salusin antibody, cardiovascular peptide,
cardiovascular
|
|
|
|
|
